The new generation weight-loss drug developed by the U.S. biotechnology company Metsera, Inc. (MTSR) demonstrated excellent ...

The Financial Times reports on Novo Nordisk's challenge to Pfizer, Comcast's talks to acquire ITV, Messina Group's stake sale ...

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) reported a rise in third-quarter revenue and earnings but surprised ...

Novo Nordisk A/S has again increased its offer for Metsera Inc. as its takeover battle with Pfizer Inc. for the obesity ...

Pfizer and Novo Nordisk are engaged in an intense bidding war for Metsera, a biotech company known for developing obesity drugs. Novo has raised its offer above Pfizer's $10 billion bid, escalating ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its ...

Pfizer and Novo Nordisk’s bidding war for the weight loss drugmaker Metsera is intensifying. Five updates: 1. Pfizer matched Novo Nordisk’s $10 billion bid for the biotech firm Nov. 5, one day after ...

By TOM MURPHY, Associated Press The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. […] ...

The 72-week multinational phase 3 ATTAIN-2 trial randomized 1613 participants with obesity or overweight (BMI ≥ 27.0) and T2D ...

The battle for obesity drug maker Metsera has escalated into a high-stakes bidding war between two pharmaceutical giants, ...

President Donald Trump's administration confirmed Thursday that it has reached a deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to ...